U.S. markets open in 9 hours 1 minute
  • S&P Futures

    4,156.00
    -4.00 (-0.10%)
     
  • Dow Futures

    34,111.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    13,467.25
    -23.75 (-0.18%)
     
  • Russell 2000 Futures

    2,236.90
    +0.30 (+0.01%)
     
  • Crude Oil

    65.70
    +0.07 (+0.11%)
     
  • Gold

    1,787.90
    +3.60 (+0.20%)
     
  • Silver

    26.57
    +0.07 (+0.26%)
     
  • EUR/USD

    1.2005
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5840
    -1.5920 (-100.00%)
     
  • Vix

    19.15
    -19.48 (-100.00%)
     
  • GBP/USD

    1.3900
    -0.0008 (-0.06%)
     
  • USD/JPY

    109.3700
    +0.1810 (+0.17%)
     
  • BTC-USD

    57,308.98
    +2,520.31 (+4.60%)
     
  • CMC Crypto 200

    1,473.33
    +68.02 (+4.84%)
     
  • FTSE 100

    7,039.30
    +116.13 (+1.68%)
     
  • Nikkei 225

    29,308.91
    +496.31 (+1.72%)
     

Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Bicycle Therapeutics PLC Sponsored ADR BCYC shares ended the last trading session 5.9% higher at $32.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.7% gain over the past four weeks.

The company's progress with its pipeline has been encouraging. The company reported encoraging development updates last month. These have boosted investor's confidence. Positive pipeline outcomes will likely drive share prices going forward.

Price and Consensus

Price Consensus Chart for BCYC
Price Consensus Chart for BCYC

This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -4.8%. Revenues are expected to be $1.95 million, up 72.5% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Bicycle Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has been revised 15.1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BCYC going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bicycle Therapeutics PLC Sponsored ADR (BCYC) : Free Stock Analysis Report

To read this article on Zacks.com click here.